奈达铂联合长春瑞滨治疗中晚期食管癌27例疗效分析

目的 观察奈达铂联合长春瑞滨治疗中晚期食管癌的近期疗效与毒副反应.方法 对27例中晚期食管癌患者给予奈达铂80 mg/m2,第1天;长春瑞滨 25 mg/m2 ,第1天、第8天.每21 d为1个周期,至少应用2个周期.结果 CR（2/27）为5.5%,PR（13/27）为48.1%, SD（7/27）为25.5%,PD（5/27）为18.5%,有效率（RR）为55.5 %（15/27）.主要毒副反应为骨髓抑制,表现为白细胞与血小板减少,以Ⅰ～Ⅲ度为主,Ⅲ～Ⅳ度骨髓抑制37.3%（10/27）.结论 奈达铂联合长春瑞滨治疗中晚期食管癌疗效较好,毒副反应小,可临床推广.

Effects of nedaplatin plus vinorelbine in treatment of middle and advanced esophageal cancer

Objective To evaluate efficacy and toxic reactions of nedaplatin plus vinorelbine in treatment of middle and advanced esophageal cancer. Methods 27 patients with esophageal cancer patients, nedaplatin 80 mg/m2, d1, vinorel- bine 25 mg/m2,dl and dS. Every 21 days for a cycle, at least two cycles. Results The overall response rate was 55.5 % （15/27） , with CR 5.5% （2/27） , PR 48.1% （ 13/27 ）. SD 25.5% （7/27） and PD 18.5 % （ 5/27 ）. The major toxicity was myelosuppression for white and thrombocytopenia, forⅠ-Ⅲ incidence degree. Ⅲ-Ⅳdegrees 37.3% （10/27）. Conclusion Nedaplatin plus vinorelbine rather active in treating middle and advanced esophageal cancer with acceptable talerance, and it deserves further popularization.